Suppr超能文献

新型 SARS-CoV-2 变体刺突蛋白的结构和抗原性变化。

Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.

机构信息

Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.

Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, India.

出版信息

PLoS Pathog. 2022 Feb 17;18(2):e1010260. doi: 10.1371/journal.ppat.1010260. eCollection 2022 Feb.

Abstract

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously evolving, and this poses a major threat to antibody therapies and currently authorized Coronavirus Disease 2019 (COVID-19) vaccines. It is therefore of utmost importance to investigate and predict the putative mutations on the spike protein that confer immune evasion. Antibodies are key components of the human immune system's response to SARS-CoV-2, and the spike protein is a prime target of neutralizing antibodies (nAbs) as it plays critical roles in host cell recognition, fusion, and virus entry. The potency of therapeutic antibodies and vaccines partly depends on how readily the virus can escape neutralization. Recent structural and functional studies have mapped the epitope landscape of nAbs on the spike protein, which illustrates the footprints of several nAbs and the site of escape mutations. In this review, we discuss (1) the emerging SARS-CoV-2 variants; (2) the structural basis for antibody-mediated neutralization of SARS-CoV-2 and nAb classification; and (3) identification of the RBD escape mutations for several antibodies that resist antibody binding and neutralization. These escape maps are a valuable tool to predict SARS-CoV-2 fitness, and in conjunction with the structures of the spike-nAb complex, they can be utilized to facilitate the rational design of escape-resistant antibody therapeutics and vaccines.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)病毒不断进化,这对抗体疗法和目前授权的 2019 年冠状病毒病(COVID-19)疫苗构成重大威胁。因此,调查和预测刺突蛋白上可能导致免疫逃逸的突变至关重要。抗体是人体免疫系统对 SARS-CoV-2 反应的关键组成部分,刺突蛋白是中和抗体(nAb)的主要靶标,因为它在宿主细胞识别、融合和病毒进入中发挥关键作用。治疗性抗体和疫苗的效力在一定程度上取决于病毒逃避中和的难易程度。最近的结构和功能研究已经绘制了 nAb 在刺突蛋白上的表位图谱,该图谱说明了几种 nAb 的足迹和逃逸突变的部位。在这篇综述中,我们讨论了(1)新兴的 SARS-CoV-2 变体;(2)抗体介导的 SARS-CoV-2 中和的结构基础和 nAb 分类;以及(3)几种抗体的 RBD 逃逸突变的鉴定,这些抗体抵抗抗体结合和中和。这些逃逸图谱是预测 SARS-CoV-2 适应性的有价值的工具,结合刺突-nAb 复合物的结构,可用于促进具有抗逃逸能力的抗体治疗药物和疫苗的合理设计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5e/8853550/b4e348899370/ppat.1010260.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验